Health
Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers – OncLive
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant…
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib (AMG 510) and adagrasib in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting.1,2
The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases…
-
General21 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
General19 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News23 hours agoBoat crash in Helensvale on the Gold Coast leaves man with life-threatening burns and another one injured
-
Noosa News22 hours agoBrisbane bands unite to help bassist’s cancer fight